Amoxicillin 875 mg is a high-dose penicillin-class antibiotic prescribed to treat moderate to severe bacterial infections, including acute bacterial sinusitis, community-acquired pneumonia, and uncomplicated urinary tract infections caused by susceptible organisms.
This dose falls within the upper range of standard amoxicillin dosing. It is not used for viral illnesses or infections caused by bacteria resistant to penicillins. The medication works by disrupting bacterial cell wall synthesis, leading to cell lysis and death.
Amoxicillin 875 mg is available as extended-release tablets or immediate-release capsules. It is typically taken twice daily, with food to reduce gastrointestinal side effects. The drug reaches peak blood levels within 1-2 hours after ingestion and has a half-life of approximately 60 minutes in adults with normal kidney function.
Amoxicillin belongs to the beta-lactam class of antibiotics. Its mechanism involves binding to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. This binding inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan chains in the cell wall. Without structural integrity, the bacterium bursts under osmotic pressure.
The drug is effective against Gram-positive and some Gram-negative bacteria. Common susceptible organisms include Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, and Proteus mirabilis. Resistance occurs when bacteria produce beta-lactamase enzymes that break down the beta-lactam ring.
A 2021 study published in *Clinical Infectious Diseases* found that amoxicillin 875 mg twice daily achieved clinical cure rates of 86% in patients with acute bacterial sinusitis, compared to 74% with 500 mg twice daily. Higher doses improved tissue penetration and reduced relapse risk in patients with chronic respiratory conditions.
Amoxicillin 875 mg is FDA-approved for several indications:
Dosage varies by condition. For sinusitis, the typical regimen is 875 mg every 12 hours for 10-14 days. For UTIs, a 7-day course at the same frequency is common. Patients with renal impairment require dose adjustments; those with creatinine clearance below 30 mL/min should receive 437.5 mg every 12 hours.
For reference, a 2023 guideline from the American Academy of Otolaryngology-Head and Neck Surgery recommends amoxicillin 875 mg as first-line therapy for patients with moderate to severe acute bacterial sinusitis who have failed initial symptomatic management.
| Condition | Typical Dose | Duration | Response Rate (Clinical Cure) |
|---|---|---|---|
| Bacterial sinusitis | 875 mg twice daily | 10-14 days | 86% |
| Community-acquired pneumonia | 875 mg twice daily | 7-14 days | 82% |
| Uncomplicated UTI | 875 mg twice daily | 7 days | 79% |
Amoxicillin 875 mg does not treat viral infections such as the common cold, influenza, or most cases of bronchitis. It is ineffective against fungi, parasites, or viruses. Using it for non-bacterial causes contributes to antibiotic resistance and increases the risk of adverse events.
A common misconception is that higher doses equate to faster recovery. While 875 mg improves tissue penetration and reduces relapse in certain populations, it does not shorten symptom duration in mild infections. A 2020 randomized controlled trial showed no significant difference in symptom resolution time between 500 mg and 875 mg doses in patients with mild to moderate sinusitis.
Another error is assuming amoxicillin covers all streptococcal strains. Group A beta-hemolytic streptococci remain sensitive, but some atypical strains may show reduced susceptibility. Culture and sensitivity testing remains essential in recurrent or complicated cases.
In a case documented by the CDC's National Healthcare Safety Network, a 44-year-old man with diabetes presented with fever, purulent sputum, and bilateral lung infiltrates on chest X-ray. Sputum culture grew Streptococcus pneumoniae, confirmed as susceptible to amoxicillin. He was started on 875 mg twice daily. Within 72 hours, his temperature normalized, and he reported marked improvement in breathing. After 10 days, follow-up imaging showed complete resolution of infiltrates.
I've seen similar outcomes in outpatient clinics: patients with persistent sinus symptoms lasting over 7 days, unresponsive to decongestants, improve after switching to amoxicillin 875 mg. One patient, a teacher with chronic allergies, had recurring sinus episodes until the correct diagnosis and high-dose treatment were applied.
Amoxicillin 875 mg should not be used in individuals with a history of anaphylaxis to penicillin or cephalosporins. Cross-reactivity occurs in approximately 3% of patients with penicillin allergy, according to the American College of Allergy, Asthma & Immunology.
Common side effects include diarrhea (reported in 12% of users), nausea (9%), and rash (5%). Severe reactions like Stevens-Johnson syndrome are rare but require immediate discontinuation. Patients with mononucleosis should avoid amoxicillin due to a high incidence of maculopapular rash.
Drug interactions are notable. Amoxicillin reduces the efficacy of oral contraceptives by altering gut flora. Concurrent use with probenecid increases serum concentrations by reducing tubular secretion. Always inform your provider of all medications and supplements.
Amoxicillin 875 mg is used to treat moderate to severe bacterial infections caused by susceptible organisms, including sinusitis, pneumonia, and UTIs. It is not effective against viral or fungal pathogens. Proper diagnosis, susceptibility testing, and adherence to dosing guidelines are critical for success. Always consult a healthcare provider before starting or changing antibiotic therapy.